HTDS fell over 27% today after releasing some press that we pasted below for your reading pleasure. Today was the sell-the-news event. Only the first half hour of trade was in the black.
Judging from today’s volume there are many shareholders buying on this dip and expecting more gains down the road. Over 300 million shares traded hands today. That is some very impressive volume.
HTDS could very well be setting up for a nice bounce back over $.01 tomorrow.
Keep your eyes on her.
Hard To Treat Diseases (HTDS.PK) Stem Cell Graft Survival
BELGRADE, Serbia, Aug 20, 2009 /PRNewswire-FirstCall via COMTEX/ — Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com Slavica Bio Chem www.slavicabiochem.com Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem reported that IBISS research group from Serbia has begun preliminary experiments within a project aimed at Promoting stem cell graft survival in the model of traumatic brain injury in rats. One of the goals of this project is to examine the potential role of Ribavirin in promoting survival of the stem cells transplanted after brain injury. This report with images will be posted on http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds shortly
The results of a pilot study in this project were presented at the Human Pluripotent Stem Cells symposium: interrogating disease and development, organized by Dr Stephen Sullivan and Abcam, Dublin, Ireland, April 22 – 24, 2009.
Neural stem cells (SC) are a promising therapeutic tool in CNS disease and injuries. However, there are a number of obstacles which have to be overcome in order to achieve a therapeutically beneficial outcome. These include the problem of inducing differentiation of multipotent grafted SCs into desired cell type, rejection of grafted SCs by the recipient’s immune system and glial scar formation following the injury, which can present both physical and chemical barrier to SC migration and differentiation.
In our study, we detected that daily injection of Ribavirin for 5 and 10 days considerably decreased the degree of reactive astrogliosis after traumatic brain injury in adult rats. Decrease of reactive astrogliosis leads to downregulation of glial scar formation.
However, the beneficial effects that astroglial cells can exert on recovery after injury should not be neglected. Our group continues to test different duration times and timing of Ribavirin treatment, which we believe to be crucial in balancing the positive and negative effects that astrogliosis may have.
The results were reported in the Poster presentation session by Dr. Ivana Gadjanski, research scientist in the IBISS group. Our results drew significant consideration from the attending scientists.
URL for the Human Pluripotent Stem Cells symposium website: http://www.abcam.com/index.html?pageconfig=resource rid=11610 utm_campaign=Event.ESCIE utm_source=Abcam.Events utm_medium=Email utm_term=12494-Dublinemail intGoUser=3166517
In other company events: As previously announced the set up of a new, redesigned website for the subsidiary Slavica Biochem (http://www.slavicabiochem.com/) has been completed and the web site launched. The new website presents updated information material on the research topics of the Slavica Biochem medical team from Belgrade, Serbia. The website is made in a very user-friendly format providing ample general information on the Multiple Sclerosis (MS) and Traumatic Brain Injury (TBI), as well as specific details on the methodology and results of the Slavica medical team. Patients and potential shareholders can also find, listed in a submenu on the Slavica biochem website, a number of selected links to other specialized websites dealing with MS and TBI.
The company is also in the process of redesigning and launching its HTDS website shortly as well www.htdsmedical.com. The company intends to provide further updates on a timely and ongoing basis.
Safe Harbor Statement:
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision’s under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact email@example.com; For any corporate matters, please contact firstname.lastname@example.org, www.htdsmedical.com
SOURCE Hard to Treat Diseases
Copyright (C) 2009 PR Newswire. All rights reserved